Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Clovis Oncology Inc    CLVS

CLOVIS ONCOLOGY INC

(CLVS)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Clovis Oncology : to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:03am EST

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.

The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.

Conference Call Details

Clovis will hold a conference call to discuss Q4/FY 2018 results on Tuesday, February 26, at 8:30am ET. The conference call will be simultaneously webcast on the Company’s web site at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: US participants 866.393.4306, International participants 734.385.2616, conference ID: 6675335.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the U.S. and Europe.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLOVIS ONCOLOGY INC
02/12CLOVIS ONCOLOGY : to Announce Fourth Quarter/Fiscal Year 2018 Financial Results ..
BU
01/24CLOVIS ONCOLOGY : Announces European Commission Authorization of Rubraca®▼..
BU
01/07Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy
RE
01/07CLOVIS ONCOLOGY, INC. : Results of Operations and Financial Condition, Financial..
AQ
01/07CLOVIS ONCOLOGY : Download PDF format download (opens in new window)
PU
01/07CLOVIS ONCOLOGY : Announces Product Revenues for the Fourth Quarter and Full Yea..
BU
01/04BMS deal weighs on Celgene partners
AQ
01/02CLOVIS ONCOLOGY : Download PDF format download (opens in new window)
PU
01/02CLOVIS ONCOLOGY : to Present at the 37th Annual J.P. Morgan Healthcare Conferenc..
BU
2018CLOVIS ONCOLOGY : Download PDF format download (opens in new window)
PU
More news
Financials ($)
Sales 2018 91,5 M
EBIT 2018 -324 M
Net income 2018 -355 M
Debt 2018 50,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 15,2x
EV / Sales 2019 11,6x
Capitalization 1 344 M
Chart CLOVIS ONCOLOGY INC
Duration : Period :
Clovis Oncology Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLOVIS ONCOLOGY INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 29,2 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Patrick J. Mahaffy President, Chief Executive Officer & Director
Michael James Barrett Chairman
Daniel W. Muehl CFO, Principal Accounting Officer & SVP-Finance
Gillian C. Ivers-Read Chief Regulatory Officer & Executive VP
Lindsey Rolfe Chief Medical Officer & Executive VP-Clinical
Sector and Competitors
1st jan.Capitalization (M$)
CLOVIS ONCOLOGY INC41.93%1 344
GILEAD SCIENCES8.06%87 436
VERTEX PHARMACEUTICALS13.49%48 081
REGENERON PHARMACEUTICALS13.51%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252